Quantbot Technologies LP Sells 15,044 Shares of Privia Health Group, Inc. (NASDAQ:PRVA)

Quantbot Technologies LP decreased its holdings in Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 40.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,331 shares of the company's stock after selling 15,044 shares during the period. Quantbot Technologies LP's holdings in Privia Health Group were worth $437,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. First Horizon Advisors Inc. boosted its position in Privia Health Group by 53.8% during the fourth quarter. First Horizon Advisors Inc. now owns 1,807 shares of the company's stock valued at $35,000 after purchasing an additional 632 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Privia Health Group by 7,833.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,380 shares of the company's stock valued at $47,000 after buying an additional 2,350 shares in the last quarter. Financial Management Professionals Inc. acquired a new position in Privia Health Group in the fourth quarter worth approximately $51,000. Quarry LP raised its position in Privia Health Group by 344.6% during the third quarter. Quarry LP now owns 3,268 shares of the company's stock valued at $60,000 after acquiring an additional 2,533 shares in the last quarter. Finally, Neo Ivy Capital Management bought a new stake in Privia Health Group in the third quarter worth approximately $66,000. 94.48% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. Macquarie assumed coverage on shares of Privia Health Group in a report on Monday, December 16th. They set an "outperform" rating and a $25.00 price target on the stock. JMP Securities set a $29.00 price target on Privia Health Group in a research note on Friday, February 28th. Stephens reissued an "overweight" rating and issued a $26.00 price objective on shares of Privia Health Group in a research note on Thursday, January 2nd. Piper Sandler boosted their target price on Privia Health Group from $25.00 to $40.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. Finally, Canaccord Genuity Group increased their price target on Privia Health Group from $29.00 to $30.00 and gave the company a "buy" rating in a report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $26.67.

Remove Ads

Privia Health Group Stock Down 2.3 %

NASDAQ PRVA traded down $0.52 during midday trading on Wednesday, hitting $22.36. The company had a trading volume of 589,097 shares, compared to its average volume of 771,430. The firm has a fifty day simple moving average of $23.80 and a two-hundred day simple moving average of $21.26. Privia Health Group, Inc. has a fifty-two week low of $15.92 and a fifty-two week high of $26.04. The stock has a market cap of $2.69 billion, a price-to-earnings ratio of 223.62, a P/E/G ratio of 3.47 and a beta of 0.85.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.